A comparison between the effects of low dose (1 μg) and standard dose (250 μg) ACTH stimulation tests on adrenal P450c17α enzyme activity in women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 147, Issue 4, 2002, Pages 473-477

  Çolak, Ramiz ^a   Keleştimur, Fahrettin ^a   Ünlühizarci, Kürşad ^a   Bayram, Fahri ^a   Şahin, Yilmaz ^a   Tutuş, Ahmet ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; CYTOCHROME P450C17; HYDROCORTISONE; HYDROXYPROGESTERONE; PRASTERONE SULFATE; TETRACOSACTIDE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; FOLLICULAR PHASE; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERANDROGENISM; LOW DRUG DOSE; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROVOCATION TEST;

EID: 0036772737     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470473     Document Type: Article

References (34)

1. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-861.
2. Kandarakis ED & Dunaif A. New perspectives in polycystic ovary syndrome. Trends in Endocrinology and Metabolism 1996 7 267-271.
3. Rosenfield RL, Barnes RB, Cara JF & Lucky AW. Dysregulation of cytochrome P450c17α as the cause of polycystic ovary syndrome. Fertility and Sterility 1990 53 785-791.
4. Şahin Y & Keleştimur F. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clinical Endocrinology 1993 39 151-155.
5. Martikainen H, Salmela P, Nuojua-Huttunen S, Perala J, Leinonen S, Knip M et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertility and Sterility 1996 66 564-570.
6. Turner EI, Watson MJ, Perry LA & White MC. Investigation of adrenal function in women with oligomenorrhea and hirsutism (clinical PCOS) from the north-east of England using an adrenal stimulation test. Clinical Endocrinology 1992 36 389-397.
7. Azziz R, Rafi A, Smith BR, Bradley EL & Zacur HA. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 1990 70 431-436.
8. Kirnap M, Çolak R, Eser C, Özsoy O, Tutuş A & Keleştimur F. A comparison between low dose (1 μg), standard dose (250 μg) ACTH stimulation tests and insulin tolerance test (ITT) in the evaluation of hypothalamo-pituitary-adrenal (HPA) axis in primary fibromyalgia syndrome. Clinical Endocrinology 2001 55 455-459.
9. Dökmetaş HS, Çolak R, Keleştimur F, Selçuklu A, Ünlühizarci K & Bayram F. A comparison between the 1 μg adrenocorticotropin (ACTH) test, short ACTH (250 μg) test and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. Journal of Clinical Endocrinology and Metabolism 2000 85 3713-3719.
10. Ünlühizarci K, Bayram F, Güven M, Kula M, Çolak R & Keleştimur F. Cortisol responses to low (1 μg) and standard (250 μg) dose ACTH stimulation tests in patients with primary hypothyroidism. Clinical Endocrinology 2001 54 699-702.
11. Laureti S, Arva E, Candeloro P, Di Vito L, Ghigo E, Santeusanio F et al. Low dose (1 μg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clinical Endocrinology 2000 53 107-115.
12. Patel L & Clayton PE. Clinical usefulness of the low dose ACTH test. Journal of Endocrinological Investigation 1999 22 401-404.
13. Thaler LM & Blevins LS. The low dose (1 μg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism 1999 83 2726-2729.
14. Zawadki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, F Haseltine & GR Merriam. Boston: Blackwell, 1992.
15. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology and management. American Journal of Obstetrics and Gynecology 1981 140 815-830.
16. Azziz R, Dewailly D & Owebach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. Journal of Clinical Endocrinology and Metabolism 1994 78 810-815.
17. Dickstein G, Shechner C, Nicholson WE, Rosner I. Shen-Orr Z, Adawi F et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. Journal of Clinical Endocrinology and Metabolism 1991 72 773-778.
18. Gross MD, Wortsman J, Shapiro B, Meyers LC, Woodbury MC & Ayers JW. Scintigraphic evidence of adrenal cortical dysfunction in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1986 62 197-201.
19. Şahin Y & Keleştimur F. 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone agonist buserelin and adrenocorticotropin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17α dysregulation. Human Reproduction 1997 12 910-913.
20. Ünlühizarci K, Keleştimur F, Şahin Y & Bayram F. The treatment of insulin resistance does not improve adrenal cytochrome P450c17α enzyme dysregulation in polycystic ovary syndrome. European Journal of Endocrinology 1999 140 56-61.
21. Ehrmann DA, Barnes R & Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism. Endocrine Reviews 1995 16 322-353.
22. Rodin A, Thakkar H, Taylor N & Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11-beta hydroxysteroid dehydrogenase. New England Journal of Medicine 1994 330 460-465.
23. La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A & De Leo V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertility and Sterility 1999 72 985-989.
24. Gonzalez F, Chang L, Horab T & Lobo AR. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Fertility and Sterility 1996 66 354-361.
25. Azziz R, Rittmaster RS, Fox LM, Bradley RE, Potter D & Boots LR. Role of the ovary in the adrenal androgen excess of hyperandrogenic women. Fertility and Sterility 1998 69 851-859.
26. Escobar-Morreale HF, Serrano-Gottaredona J, Garcia-Robles R, Sancho JM & Varela C. Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Fertility and Sterility 1997 67 654-662.
27. Gibson M, Lackritz R, Schiff I & Tulchinsky D. Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertility and Sterility 1980 33 43-48.
28. Şahin Y & Keleştimur F. The frequency of late-onset 21 hydroxylase and 11-beta hydroxylase deficiency in women with polycystic ovary syndrome. European Journal of Endocrinology 1997 137 670-674.
29. Escobar-Morreale H, Pazos F, Potau N, Garcia-Robles R, Sancho JM & Varela C. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperandrogenism: role of adrenal and ovarian cytochrome P450c17 alpha. Fertility and Sterility 1994 62 521-530.
30. Chang RJ, Mandel FP, Wolfsen AR & Judd HL. Circulating levels of plasma adrenocorticotropin in polycystic ovary disease. Journal of Clinical Endocrinology and Metabolism 1982 54 1265-1267.
31. Azziz R, Black V, Hines GA, Fox LM & Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. Journal of Clinical Endocrinology and Metabolism 1998 83 2317-2323.
32. Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K & Lobo AR. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome. Fertility and Sterility 1999 71 439-444.
33. Carmina E, Gonzalez F, Vidali A, Stanczyk FZ, Ferin M & Lobo RA. The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Human Reproduction 1999 14 307-311.
34. Carmina E, Rosato F & Janni A. Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients. Journal of Endocrinological Investigation 1986 9 5-9.